| Ethical issues in gender-affirming care for youth LL Kimberly, KMB Folkers, P Friesen, D Sultan, GP Quinn, ... Pediatrics 142 (6), 2018 | 87 | 2018 |
| Medical crowdfunding for scientifically unsupported or potentially dangerous treatments F Vox, KMB Folkers, A Turi, AL Caplan Jama 320 (16), 1705-1706, 2018 | 59 | 2018 |
| Multinuclear NMR and MRI reveal an early metabolic response to mTOR inhibition in sarcoma V Di Gialleonardo, HN Aldeborgh, V Miloushev, KM Folkers, K Granlund, ... Cancer research 77 (11), 3113-3120, 2017 | 20 | 2017 |
| Effects of Vacuolar H+-ATPase Inhibition on Activation of Cathepsin B and Cathepsin L Secreted from MDA-MB231 Breast Cancer Cells A Uhlman, K Folkers, J Liston, H Pancholi, A Hinton Cancer Microenvironment 10, 49-56, 2017 | 19 | 2017 |
| Federal Right to Try: where is it going? K Folkers, C Chapman, B Redman Hastings Center Report 49 (2), 26-36, 2019 | 17 | 2019 |
| Improving expanded access in the United States: the role of the institutional review board KMB Folkers, A Bateman-House Therapeutic innovation & regulatory science 52 (3), 285-293, 2018 | 13 | 2018 |
| Charlie Gard and the limits of parental authority A Caplan, KMB Folkers Hastings Center Report 47 (5), 15-16, 2017 | 12 | 2017 |
| Paying for unapproved medical products KMB Folkers, A Bateman-House, C Robertson Wake Forest JL & Pol'y 11, 85, 2020 | 11 | 2020 |
| Patient advocacy organizations’ information for patients on pre-approval access to investigational treatments KMB Folkers, S Leone, A Caplan BMC Research Notes 12, 1-4, 2019 | 8 | 2019 |
| Single-patient expanded access requests: IRB professionals’ experiences and perspectives CR Chapman, JA Shearston, KMB Folkers, BK Redman, A Caplan, ... AJOB Empirical Bioethics 10 (2), 88-99, 2019 | 8 | 2019 |
| Zika, sexual transmission and prudent public health policy KM Folkers, AL Caplan, LH Igel Public Health 148, 66-68, 2017 | 8 | 2017 |
| Meaningful use of electronic health records for quality assessment and review of clinical ethics consultation S Sanelli-Russo, K McBride Folkers, W Sakolsky, JJ Fins, ... The Journal of Clinical Ethics 29 (1), 52-61, 2018 | 7 | 2018 |
| Navigating Evolving Ethical Questions in Decision Making for Gender-Affirming Medical Care for Adolescents CSH Laura Kimberly, Kelly McBride Folkers, Baer Karrington, Jeremy Wernick ... Journal of Clinical Ethics 32 (4), 2021 | 5 | 2021 |
| Medical crowdfunding’s dark side F Vox, KMB Folkers, AL Caplan Health Affairs Forefront, 2018 | 5 | 2018 |
| The critical role of medical institutions in expanding access to investigational interventions K Spector‐Bagdady, KJ Weatherwax, M Gravelin, AG Shuman Hastings Center Report 49 (2), 36-39, 2019 | 4 | 2019 |
| 'Right To Try'Won’t Give Patients Access To Experimental Drugs. Here’s What Will. A Bateman-House, KMB Folkers, AL Caplan Health Affairs Forefront, 2017 | 4 | 2017 |
| False hope about coronavirus treatments K McBride Folkers, A Caplan The Hastings Center, 2020 | 3 | 2020 |
| Ensuring justice in access to investigational neurological drugs L Kearns, A Bateman-House, A Caplan Seminars in Neurology 38 (05), 583-588, 2018 | 3 | 2018 |
| Preapproval Nontrial Access and Off-Label Use: Do They Meet Criteria for Dual-Deviation Review? CR Chapman, KMB Folkers, A McFadyen, LD Shah, A Bateman-House The American Journal of Bioethics 19 (6), 22-25, 2019 | 2 | 2019 |
| Private equity and right to try: a dangerous combination HF Lynch, KMB Folkers, AL Caplan Health Affairs Forefront, 2020 | 1 | 2020 |
